TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01418300
Drug: sequential versus triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
Study: NCT03890302
Drug: FB704A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT03890302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
Study: NCT00206674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
Study: NCT03136068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-abdominal injection
Study: NCT01071395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill given 3 times daily
Study: NCT02766608
Drug: BFF MDI 320/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded Treatment
Study: NCT02766608
Drug: BFF MDI 160/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded Treatment
Study: NCT02766608
Drug: FF MDI 9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded Treatment
Study: NCT02766608
Drug: Symbicort® TBH 400/12 μg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Label
Study: NCT02343458
Drug: GP MDI (PT001)
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
Study: NCT02343458
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
Study: NCT02326103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01610700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each actuation of placebo delivered the excipients only.
Study: NCT01405391
Drug: PM01183
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Study: NCT02401256
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study: NCT00359112
Drug: sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03811912
Drug: CTP-543 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as tablets to aid treatment masking.
Study: NCT01156753
Drug: Investigator's Choice chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Study: NCT01782131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
Study: NCT04367168
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Study: NCT01346657
Drug: Nifidipine & LipoCol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
Study: NCT02157311
Drug: Four consecutive days on treatment and 3 days off
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
Study: NCT03108534
Drug: CHF1535 NEXThaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment
Study: NCT03108534
Drug: CHF1535 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment
Study: NCT03108534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment
Study: NCT02451748
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: some patients are on 1000 mg/day of naproxen
Study: NCT02451748
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
Study: NCT03696121
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
Study: NCT01415505
Drug: Nebivolol, Valsartan and Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Study: NCT00014573
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02544984
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study: NCT02544984
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study: NCT00408993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every day (QD), by mouth (PO)
Study: NCT02696850
Drug: Saline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
Study: NCT00171587
Drug: PTK787/ZK 222584 (vatalanib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03738865
Drug: G-Pen
Normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Study: NCT02488486
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02298218
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
Study: NCT00581945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to ACZ885 administered via intravenous infusion.
Study: NCT02669030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group
Study: NCT02048761
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
Study: NCT04321837
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate
Study: NCT00767000
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 tablets three times daily
Study: NCT00767000
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-0941 three times daily
Study: NCT02912533
Drug: JR-131
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02528201
Drug: Celecoxib 200 milligrams
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 milligrams once a day
Study: NCT02528201
Drug: Celecoxib 400 milligrams
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400 milligrams once a day
Study: NCT02528201
Drug: diclofenac 50 milligrams
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 50 milligrams three times a day
Study: NCT01194115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo representing standard of care
Study: NCT00126451
Drug: Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02065440
Drug: Rhinoebastel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
Study: NCT02065440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
Study: NCT01116245
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
Study: NCT02060396
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of Adiro 100 mg will be administered daily orally for 7 days.
Study: NCT00052065
Drug: TLK286
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00692939
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mobilization
Study: NCT04894864
Drug: Opioid-Based Anesthesia-Analgesia Strategy
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
Study: NCT04894864
Drug: Opioid-free Anesthesia-Analgesia Strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
Study: NCT02833831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered.
Study: NCT00425438
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
Study: NCT00425438
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
Study: NCT00425438
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
Study: NCT04594694
Drug: OCA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet daily for the remainder of the study
Study: NCT02760407
Drug: Placebo q2w
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study: NCT00673673
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
Study: NCT01462292
Drug: GSK2402968 3mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 2 doses of GSK2402968
Study: NCT01462292
Drug: GSK2402968 6 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 2 doses of GSK2402968
Study: NCT01462292
Drug: Placebo to match GSK2402968 3 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01462292
Drug: Placebo to match GSK2402968 6 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT00510692
Drug: Eicosapentanoic Acid (EPA)
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 500mg EPA capsules twice daily for 6 months
Study: NCT00510692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500mg placebo capsules twice daily for 6 months
Study: NCT03156153
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Study: NCT03156153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Study: NCT00945191
Drug: CS-1008
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
Study: NCT00997685
Drug: Capecitabine plus oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles
Study: NCT01475292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via a nebuliser once daily for 14 days
Study: NCT03399110
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2
Study: NCT03048097
Drug: Fluorodeoxyglucose
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
Study: NCT00721526
Drug: disulfiram plus lorazepam
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
Study: NCT00353704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of saccharose (placebo) was administered about one hour before surgery
Study: NCT00221845
Drug: ACE Inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Study: NCT00221845
Drug: Intensified Blood Pressure Control
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Study: NCT00221845
Drug: Add-on Angiotensin Receptor Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Study: NCT02613572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00458250
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00458250
Drug: CAMPATH-1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00458250
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03587324
Drug: Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
Approvals — FDA: no, EMA: no, PMDA: no
Description: To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)
Study: NCT02654119
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01303627
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
Study: NCT01159496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, once daily for 14 days
Study: NCT01376752
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
Study: NCT02504645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100463
Drug: 0.1% Uracil Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily lotion to prevent HFS
Study: NCT00003498
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT01513850
Drug: Hepabulin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V.
Study: NCT01620463
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
Study: NCT04478097
Drug: CKD-330 Tab. and D086 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT04478097
Drug: CKD-333 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1T
Study: NCT01259544
Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of powder form dissolved in one cup of tap water prior to breath test
Study: NCT01259544
Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
Study: NCT02681211
Drug: Ketorolac 0.5mg/kg, max 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL
Study: NCT00872898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, once daily, oral administration.
Study: NCT04544826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.
Study: NCT00681317
Drug: AZD6280
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03963895
Drug: AB002 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
Study: NCT03963895
Drug: AB002 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
Study: NCT03963895
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered on Day 1 as a single intravenous infusion
Study: NCT00606424
Drug: 20 mCi dose for a 50 kg individual of [F-18]HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
Study: NCT00958919
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml
Study: NCT00795600
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin NPH once daily plus insulin aspart at mealtime
Study: NCT00736996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet daily for 6 months
Study: NCT03660683
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablets